{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:44:35Z","timestamp":1792784675014,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014423","name":"Environmental Restoration and Conservation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0410055"],"award-info":[{"award-number":["JP19ek0410055"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0410040"],"award-info":[{"award-number":["JP17ek0410040"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ek0109062"],"award-info":[{"award-number":["JP16ek0109062"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Society of Laboratory Medicine Fund for Promotion of Scientific Research"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["15KK0329"],"award-info":[{"award-number":["15KK0329"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["16K08926"],"award-info":[{"award-number":["16K08926"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["17K09993"],"award-info":[{"award-number":["17K09993"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["17H04344"],"award-info":[{"award-number":["17H04344"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Labour Sciences Research"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maruho","id":[{"id":"https:\/\/ror.org\/05hj3gh79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Kyorin, Taiho"},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maruho, Tsumura"},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.alit.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T08:04:25Z","timestamp":1583136265000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":200,"title":["The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-5901","authenticated-orcid":false,"given":"Hiroyuki","family":"Nagase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-7735","authenticated-orcid":false,"given":"Shigeharu","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeharu","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2020.02.002_bib1","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood-2012-07-443424","article-title":"Use of 111-Indium-labeled autologous eosinophils to establish the in\u00a0vivo kinetics of human eosinophils in healthy subjects","volume":"120","author":"Farahi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.alit.2020.02.002_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1","article-title":"Eosinophil infiltration and degranulation in normal human tissue","volume":"252","author":"Kato","year":"1998","journal-title":"Anat Rec"},{"key":"10.1016\/j.alit.2020.02.002_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.MCHD-0020-2015","article-title":"The regulatory function of eosinophils","volume":"4","author":"Wen","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.alit.2020.02.002_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"G.M.-C.S.F., IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.alit.2020.02.002_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.12688\/f1000research.11133.1","article-title":"Recent advances in understanding eosinophil biology","volume":"6","author":"Klion","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.alit.2020.02.002_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.alit.2015.03.004","article-title":"Group 2 innate lymphoid cells and asthma","volume":"64","author":"Kabata","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.02.002_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)80294-0","article-title":"IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses","volume":"4","author":"Kopf","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.alit.2020.02.002_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","article-title":"Eosinophilia in transgenic mice expressing interleukin 5","volume":"172","author":"Dent","year":"1990","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2020.02.002_bib9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/all.13146","article-title":"Dysregulation of interleukin 5 expression in familial eosinophilia","volume":"72","author":"Prakash Babu","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib10","doi-asserted-by":"crossref","first-page":"C623","DOI":"10.1152\/ajpcell.1998.275.3.C623","article-title":"The mechanism of IL-5 signal transduction","volume":"275","author":"Adachi","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.alit.2020.02.002_bib11","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1084\/jem.185.12.2143","article-title":"Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma","volume":"185","author":"Lee","year":"1997","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2020.02.002_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0091-6749(92)90067-C","article-title":"The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa","volume":"90","author":"Terada","year":"1992","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00016489309130242","article-title":"Interleukin-5 preferentially recruits eosinophils from vessels in nasal mucosa","volume":"506","author":"Terada","year":"1993","journal-title":"Acta Otolaryngol Suppl"},{"key":"10.1016\/j.alit.2020.02.002_bib14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1365-2222.2005.02335.x","article-title":"Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation","volume":"35","author":"Malm-Erjefalt","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fimmu.2019.00074","article-title":"Eotaxin-3 as a plasma biomarker for mucosal eosinophil infiltration in chronic rhinosinusitis","volume":"10","author":"Yamada","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib16","doi-asserted-by":"crossref","first-page":"18478","DOI":"10.1073\/pnas.0804547105","article-title":"Eosinophil granules function extracellularly as receptor-mediated secretory organelles","volume":"105","author":"Neves","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.alit.2020.02.002_bib17","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.4049\/jimmunol.181.11.7689","article-title":"Retinoic acids are potent inhibitors of spontaneous human eosinophil apoptosis","volume":"181","author":"Ueki","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2018.01.013","article-title":"ICAM-1 upregulation is not required for retinoic acid-induced human eosinophil survival","volume":"196","author":"Ueki","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.alit.2020.02.002_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.11.024","article-title":"Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis","volume":"133","author":"Saffari","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/thorax.56.5.341","article-title":"Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease","volume":"56","author":"Erjefalt","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2020.02.002_bib21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/rccm.201311-2069OE","article-title":"Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma","volume":"189","author":"Persson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib22","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.alit.2020.02.002_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.2011.01026.x","article-title":"Eosinophils: multifaceted biological properties and roles in health and disease","volume":"242","author":"Kita","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.alit.2020.02.002_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2017.06.033","article-title":"Sputum autoantibodies in patients with severe eosinophilic asthma","volume":"141","author":"Mukherjee","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s12276-018-0136-8","article-title":"Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma","volume":"50","author":"Choi","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.alit.2020.02.002_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaci.2017.07.048","article-title":"Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus","volume":"141","author":"Muniz","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.alit.2017.08.002","article-title":"Mucus plugging in allergic bronchopulmonary aspergillosis: implication of the eosinophil DNA traps","volume":"67","author":"Omokawa","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.02.002_bib28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.alit.2017.11.007","article-title":"ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media","volume":"67","author":"Ohta","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.02.002_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2015.04.041","article-title":"Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes","volume":"137","author":"Ueki","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11882-016-0634-5","article-title":"Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation","volume":"16","author":"Ueki","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.alit.2020.02.002_bib31","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2018-04-842260","article-title":"Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death","volume":"132","author":"Ueki","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.alit.2020.02.002_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2147\/COPD.S115969","article-title":"Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease?","volume":"12","author":"Uribe Echevarria","year":"2017","journal-title":"Int J Chron Obstr Pulmon Dis"},{"key":"10.1016\/j.alit.2020.02.002_bib33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2340\/00015555-2050","article-title":"Mass spectrometry of flame figures","volume":"95","author":"Wouters","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2020.02.002_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2014.00496","article-title":"Eosinophil secretion of granule-derived cytokines","volume":"5","author":"Spencer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.190.4.487","article-title":"Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon \u03b3): inhibition by immunoglobulin a complexes","volume":"190","author":"Woerly","year":"1999","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2020.02.002_bib36","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.02.002_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1189\/jlb.3A0416-166R","article-title":"SiglecF+Gr1hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice","volume":"101","author":"Percopo","year":"2017","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.alit.2020.02.002_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.200307-1004OC","article-title":"Sputum CD34+IL-5R\u03b1+ cells increase after allergen: evidence for in situ eosinophilopoiesis","volume":"169","author":"Dorman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaci.2004.09.022","article-title":"Increased eosinophil-lineage committed progenitors in the lung of allergen-challenged mice","volume":"115","author":"Southam","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2567.2010.03349.x","article-title":"Local proliferation and mobilization of CCR3+ CD34+ eosinophil-lineage-committed cells in the lung","volume":"132","author":"Radinger","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.alit.2020.02.002_bib41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0022-3565(24)35210-3","article-title":"Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys","volume":"291","author":"Zia-Amirhosseini","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.alit.2020.02.002_bib42","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-respons\u00ecveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.02.002_bib43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A\u00a0study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.02.002_bib46","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2020.02.002_bib48","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/HAB-2009-0198","article-title":"Establishment of humanized anti-interleukin-5 receptor \u03b1 chain monoclonal antibodies having a potent neutralizing activity","volume":"18","author":"Koike","year":"2009","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.alit.2020.02.002_bib50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor \u03b1 mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor \u03b1 antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib52","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib53","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.02.002_bib54","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.02.002_bib55","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib56","doi-asserted-by":"crossref","first-page":"212580","DOI":"10.7573\/dic.212580","article-title":"Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?","volume":"8","author":"Menzella","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.alit.2020.02.002_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib58","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2020.02.002_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2020.02.002_bib60","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib62","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib63","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2020.02.002_bib64","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2017.11.026","article-title":"Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma","volume":"6","author":"Gunsoy","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2020.02.002_bib65","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.171.8.3977","article-title":"Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand","volume":"171","author":"Nagase","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib66","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.alit.2020.02.002_bib67","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2020.02.002_bib69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","article-title":"Two-year integrated efficacy and safety analysis of benralizumab in severe asthma","volume":"12","author":"FitzGerald","year":"2019","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib70","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-018-0968-8","article-title":"Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases","volume":"20","author":"Sridhar","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2020.02.002_bib73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib74","doi-asserted-by":"crossref","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2020.02.002_bib75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.anai.2018.12.014","article-title":"Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab","volume":"122","author":"Kurosawa","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib76","first-page":"100899","article-title":"Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab","volume":"28","author":"Matsuno","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.alit.2020.02.002_bib77","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor \u03b1 on human eosinophils: I. Loss of membrane IL-5 receptor \u03b1 on airway eosinophils and increased soluble IL-5 receptor \u03b1 in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.02.002_bib79","first-page":"523","article-title":"[Proportion of patients with asthma indicated for four biologics and comparisons of clinical background of those patients]","volume":"68","author":"Miyoshi","year":"2019","journal-title":"Arerugi"},{"key":"10.1016\/j.alit.2020.02.002_bib80","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib81","doi-asserted-by":"crossref","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2020.02.002_bib82","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"10.1016\/j.alit.2020.02.002_bib83","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.02.002_bib84","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in chronic rhinosinusitis with and without nasal polyps","volume":"5","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2020.02.002_bib85","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4193\/Rhino10.261","article-title":"Mucosal eosinophilia and recurrence of nasal polyps - new classification of chronic rhinosinusitis","volume":"49","author":"Nakayama","year":"2011","journal-title":"Rhinology"},{"key":"10.1016\/j.alit.2020.02.002_bib86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/194589240401800307","article-title":"Histopathological features of nasal polyps with asthma association: an immunohistochemical study","volume":"18","author":"Haruna","year":"2004","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.alit.2020.02.002_bib87","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.02.002_bib88","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.anl.2018.09.004","article-title":"JESREC score and mucosal eosinophilia can predict endotypes of chronic rhinosinusitis with nasal polyps","volume":"46","author":"Nakayama","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2020.02.002_bib89","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.alit.2019.07.002","article-title":"Eosinophilic chronic rhinosinusitis","volume":"68","author":"Fujieda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.02.002_bib90","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib91","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2012.02.046","article-title":"Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps","volume":"130","author":"Takabayashi","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib92","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaci.2013.04.005","article-title":"Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis","volume":"132","author":"Nagarkar","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib93","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib94","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.02.002_bib95","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.alit.2016.12.005","article-title":"Japanese guidelines for adult asthma 2017","volume":"66","author":"Ichinose","year":"2017","journal-title":"Allergol Int"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893020300137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893020300137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:09:31Z","timestamp":1761156571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893020300137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1323893020300137"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2020.02.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}